Points to consider when defining a microbial control strategy...
Friedrich von Wintzingerode, PhD, QC Lead iNeST Project (individualized Neoantigen Specific Therapy)
About this talk
Full title: Points to consider when defining a microbial control strategy for individualized ATMPs
How are individualized ATMPs different from traditional drugs and off-the-shelf ATMPs?
Microbiological testing: be smart and keep it simple
The importance of raw material control
ATMPs: A mindset challenge for Microbiologists
BioPharma Webinars aims to keep its global audience abreast of all developments in the areas of Drug Development, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality webinars, presented by the most respected people, working with companies in Pharmaceutical, Biopharmaceutical, Biologics and Biotech Industry.…